site logo

Rivaroxaban for Venous Thrombosis CAS 366789-02-8

Venous Thrombosis CAS 366789-02-8

Port:Shenzhen, China
Transport Package:Aluminum Foil Bag Inside, Then Waterproof Bag
Payment Terms: L/C, T/T, D/P, Western Union, Paypal, Money Gram
Powder: Yes
Certification: GMP, HSE, ISO 9001, USP, BP
State: Powder
Purity: >99%
Product Name: Rivaroxaban
CAS: 366789-02-8

Venous thromboembolism continues to be a major health concern despite conventional anticoagulation therapies. Rivaroxaban is a recent market introduction that directly inhibits FXa with high potency (Ki=0.4 nM; IC50=0.7 nM) and selectivity>10,000-fold over other related serine (thrombin, trypsin, plasmin, FVIIa, FIXa, FXIa, urokinase, and activated protein C). From the X-ray crystal structure, the central oxazolidinone moiety anchors the drug through two hydrogen bonds to Gly219 and directs the morpholinone group into the S4 pocket and the chlorothiophene portion into the S1 pocket. These key components may be coupled together synthetically by a couple of routes. Condensation of 3-morpholinone with 4-fluoronitrobenzene followed by catalytic hydrogenation provides N-(p-aminophenyl)morpholinone for subsequent reaction with (S)-2-(phthalimidomethyl)oxirane. With establishment of the aminoalcohol adduct, cyclization with 1,1′-carbonyldiimidazole generates the central oxazolidinone. Deprotection and acylation with 5-chlorothiophene-2-carbonyl chloride affords rivaroxaban.


Rivaroxaban is recommended as an option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism in adults.
1. Rivaroxaban (Xarelto, Bayer) is indicated for the ‘treatment of deep vein thrombosis and pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults’. For the initial treatment of acute pulmonary embolism, the recommended dosage of rivaroxaban is 15 mg twice daily for the first 21 days followed by 20 mg once daily for continued treatment and prevention of recurrent venous thromboembolism.
2. Non-Valvular Atrial Fibrillation (NVAF)* to prevent stroke & systemic embolism.
3. Acute VTE treatment & prevention of recurrent VTE [for deep vein thrombosis (DVT) and pulmonary embolism (PE)].
4. Prevention of venous thromboembolic events (VTE) in elective total hip or knee replacement surgery (THR, TKR).